877868-60-5Relevant academic research and scientific papers
TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
-
, (2016/05/02)
The invention relates to a compound of Formula I or IA and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN
-
, (2013/08/28)
The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS
-
, (2011/12/13)
The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.
2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands
Wilson, Kevin J.,van Niel, Monique B.,Cooper, Laura,Bloomfield, Dawn,O'Connor, Desmond,Fish, L. Rebecca,MacLeod, Angus M.
, p. 2643 - 2648 (2008/02/01)
This report describes the effect of replacing the central basic amine present in many known 5-HT2A ligands with an aromatic residue. We targeted the isomeric phenethylpyridines 2 and 3 and these compounds proved to be excellent leads, possessin
